ValuEngine Upgrades Vaxart (NASDAQ:VXRT) to “Buy”

ValuEngine upgraded shares of Vaxart (NASDAQ:VXRT) from a hold rating to a buy rating in a research note published on Thursday morning, ValuEngine reports.

Separately, HC Wainwright began coverage on Vaxart in a research report on Thursday, June 27th. They set a buy rating and a $2.00 target price for the company.

VXRT stock traded up $0.01 during midday trading on Thursday, reaching $0.70. The stock had a trading volume of 43,706 shares, compared to its average volume of 512,171. The company has a market capitalization of $11.05 million, a price-to-earnings ratio of -0.26 and a beta of 0.44. Vaxart has a twelve month low of $0.60 and a twelve month high of $7.60. The business’s fifty day moving average price is $0.71. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.15.

Vaxart (NASDAQ:VXRT) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter. The company had revenue of $5.41 million for the quarter. Vaxart had a negative return on equity of 127.85% and a negative net margin of 268.64%. Equities analysts anticipate that Vaxart will post -1.67 EPS for the current year.

An institutional investor recently bought a new position in Vaxart stock. Dimensional Fund Advisors LP bought a new position in shares of Vaxart Inc (NASDAQ:VXRT) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 17,616 shares of the biotechnology company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned 0.25% of Vaxart at the end of the most recent quarter. Institutional investors own 4.55% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.

Further Reading: Rule of 72

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with's FREE daily email newsletter.